Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 291

1.

Review of selected patents for cancer therapy targeting tumor angiogenesis.

Kirstein MN, Moore MM, Dudek AZ.

Recent Pat Anticancer Drug Discov. 2006 Jun;1(2):153-61. Review.

PMID:
18221033
2.

Tumor angiogenesis and therapy.

Cao Y.

Biomed Pharmacother. 2005 Oct;59 Suppl 2:S340-3. Review.

PMID:
16507405
3.

Vascular endothelial growth factor and vascular endothelial growth factor receptor inhibitors as anti-angiogenic agents in cancer therapy.

Veeravagu A, Hsu AR, Cai W, Hou LC, Tse VC, Chen X.

Recent Pat Anticancer Drug Discov. 2007 Jan;2(1):59-71. Review.

PMID:
18221053
4.

Undermining tumor angiogenesis by gene therapy: an emerging field.

Indraccolo S.

Curr Gene Ther. 2004 Sep;4(3):297-308. Review.

PMID:
15384943
5.

[Research advancement of endogenous angiogenesis inhibitors].

Wu JX, Xu BL, Huang WL.

Ai Zheng. 2005 Mar;24(3):376-84. Review. Chinese.

PMID:
15757547
6.

Antiangiogenic cancer therapy.

Cao Y.

Semin Cancer Biol. 2004 Apr;14(2):139-45. Review.

PMID:
15018898
7.

Antiangiogenic therapy for the treatment of pediatric solid malignancies.

Davidoff AM, Kandel JJ.

Semin Pediatr Surg. 2004 Feb;13(1):53-60. Review.

PMID:
14765371
8.

Antiangiogenic strategies and agents in clinical trials.

Rosen L.

Oncologist. 2000;5 Suppl 1:20-7. Review.

9.

The VEGF/Rho GTPase signalling pathway: a promising target for anti-angiogenic/anti-invasion therapy.

van der Meel R, Symons MH, Kudernatsch R, Kok RJ, Schiffelers RM, Storm G, Gallagher WM, Byrne AT.

Drug Discov Today. 2011 Mar;16(5-6):219-28. doi: 10.1016/j.drudis.2011.01.005. Epub 2011 Jan 22. Review.

PMID:
21262381
10.

Role of the microenvironment in tumor growth and in refractoriness/resistance to anti-angiogenic therapies.

Shojaei F, Ferrara N.

Drug Resist Updat. 2008 Dec;11(6):219-30. doi: 10.1016/j.drup.2008.09.001. Epub 2008 Oct 23. Review.

PMID:
18948057
11.

Tumor angiogenesis inhibitors.

Kiselev SM, Lutsenko SV, Severin SE, Severin ES.

Biochemistry (Mosc). 2003 May;68(5):497-513. Review.

PMID:
12882631
12.

Endogenous angiogenesis inhibitors as therapeutic agents: historical perspective and future direction.

Dhanabal M, Sethuraman N.

Recent Pat Anticancer Drug Discov. 2006 Jun;1(2):223-36. Review.

PMID:
18221039
13.

Vascular targeting therapy: potential benefit depends on tumor and host related effects.

Horsman MR, Bohn AB, Busk M.

Exp Oncol. 2010 Sep;32(3):143-8. Review.

PMID:
21403608
14.

Antiangiogenic therapy: targeting vascular endothelial growth factor and its receptors.

Tandle A, Libutti SK.

Clin Adv Hematol Oncol. 2003 Jan;1(1):41-8. Review.

PMID:
16227959
15.

Challenges facing antiangiogenic therapy for cancer: impact of the tumor extracellular environment.

Gagne P, Akalu A, Brooks PC.

Expert Rev Anticancer Ther. 2004 Feb;4(1):129-40. Review.

PMID:
14748663
16.

Angiogenesis and angiogenesis inhibitors: a new potential anticancer therapeutic strategy.

Ranieri G, Gasparini G.

Curr Drug Targets Immune Endocr Metabol Disord. 2001 Nov;1(3):241-53. Review.

PMID:
12477290
17.

Endogenous inhibitors of angiogenesis.

Folkman J.

Harvey Lect. 1996-1997;92:65-82. Review. No abstract available.

PMID:
15372744
18.

Angiogenesis research: guidelines for translation to clinical application.

Folkman J, Browder T, Palmblad J.

Thromb Haemost. 2001 Jul;86(1):23-33. Review.

PMID:
11487011
19.

Inhibition of tumor angiogenesis by antibodies, synthetic small molecules and natural products.

Wahl O, Oswald M, Tretzel L, Herres E, Arend J, Efferth T.

Curr Med Chem. 2011;18(21):3136-55. Review.

PMID:
21671856
20.

Anti-angiogenic therapies in cancer: achievements and open questions.

Ruegg C, Mutter N.

Bull Cancer. 2007 Sep;94(9):753-62. Review.

Supplemental Content

Support Center